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The osmotic concentration of body fluids in man is
maintained remarkably constant between 286 and
294 mOsm/kg H20 despite large variations in water
intake, This flexibility is made possible by the oper-
ation of a thirst-neurohypophyseal-renal feedback
system. This system is characterized by a very sensi-
tive osmotic control of thirst and vasopressin' secre-
tion (1 to 2% threshold) and by the action of this
hormone on its target organ, the kidney. In the kid-
ney vasopressin alters the water permeability of the
collecting duct epithelium thereby modulating the
rate of renal excretion of water. Thus, in the face of
increased water intake, the small reduction in the
tonicity of body fluids suppresses vasopressin release
and leads to maximal urinary dilution. The excretion
of the excess water thus occurs with restoration of
plasma osmolality to normal. Conversely, if water
intake is limited, a small increase in plasma os-
molality activates the organism's water conserving
mechanism by stimulating thirst and increasing the
secretion of vasopressin. Vasopressin then increases
collecting duct water permeability and thereby facil-
itates the reabsorption of water and the concentra-
tion of urine. It follows, therefore, that impairments
in either maximal diluting or concentrating abilities
will markedly decrease the range of water intake that
the patient can tolerate. The disturbances in renal
water excretion and the resultant alterations in body
tonicity are the subjects of this paper.
Disorders of urinary concentration
With the movement of living organisms from an
aquatic to an arid terrestrial environment in which
water availability was limited, the development of a
water conserving mechanism became critical to sur-
'Unless otherwise indicated the term vasopressin refers to arginine
vasopressin. Antidiuretic hormone (ADH) and vasopressin will
be used interchangeably.
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vival [1]. Mammals rose to this challenge by devel-
oping a hairpin loop between the proximal and distal
tubule that, acting as a countercurrent multiplier,
allows for the elaboration of a urine that is more
concentrated than blood. The excretion of a concen-
trated urine has the net effect of returning free water
to the organism for dilution of body fluids. It must be
emphasized, however, that man, as well as other
mammals with the possible exception of the desert
rodent, cannot maintain water homeostatis by max-
imal urinary concentration alone. In a maximal an-
tidiuretic state in man of 1200 mOsm/kg, an average
daily solute excretion of 600 mOsm obligates a urine
loss of 500 ml/day. Even if insensible losses were
balanced by water formed by oxidation, the 500 ml of
urine loss would be the minimum intake required to
maintain balance. It is thus the precise interplay be-
tween the vasopressin-mediated elaboration of a con-
centrated urine on the one hand and an intact thirst
mechanism on the other that prevents water deple-
tion. In fact, even a severe defect in renal water
conservation need not be accompanied by significant
water depletion if thirst remains intact and is able to
compensate for the defect by commensurately in-
creasing water intake. Conversely, in the presence of
maximal concentrations of vasopressin, the normal
kidney can effectively compensate for a limitation in
water availability, although not to complete depriva-
tion thereof. Since the physiology and pathology of
thirst control have been dealt with in another section
of this symposium we shall limit the present dis-
cussion to disorders of renal water conservation.
Such disorders are characterized by failure to elabo-
rate a maximally concentrated urine in response to
osmolar [2] or nonosmolar [3] stimuli. Such a failure
can be due to either a low circulating concentration
of antidiuretic hormone (ADH) (pituitary diabetes
insipidus) or to an impaired renal response to max-
imal levels of the hormone (nephrogenic diabetes in-
sipidus).
Pituitary diabetes insipidus. Defects in the central
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synthesis or secretion of vasopressin bring about a
limitation in maximal urinary concentration and thus
to varying degrees of polyuria and polydipsia de-
pending on the severity of the defect. The disease can
be produced in experimental animals [4]. Destruction
of the supraoptic nuclei and paraventricular nuclei,
both of which synthesize vasopressin and oxytocin, is
needed for the development of a permanent lesion.
This can be accomplished only by section of the
hypophyseal-hypothalamic tract above the median
emminence. Interruption of the tract at the level of
the sella turcica allows for retrograde degeneration of
the hypothalamic nuclei, but the disease is transient
in nature [5]. The development of the diabetes insip-
idus syndrome that is associated with injury to the
tract follows a triphasic pattern [6] which is similar to
the one observed after either traumatic or surgical
injury to the same area in man [7]. The first phase is
one of profound polyuria and polydipsia which may
last from hours to five to six days and is then followed
by a period of approximately equal duration charac-
terized by a persistent antidiuresis probably due to a
discharge of vasopressin from the injured axons [8].
In this phase, a water load does not lead to urinary
dilution and persistent intake can culminate in water
intoxication [9]. In such patients, once adrenal in-
sufficiency has been ruled out as the cause for the
abnormal water excretion, water restriction must be
instituted. Following this phase again a state of dia-
betes insipidus ensues which, depending on the extent
of the injury, may be either temporary or permanent,
and complete or partial. While an idiopathic form of
vasopressin-sensitive diabetes insipidus still accounts
for as many as 50% of the patients with the disease
[10], the various forms of hypophysectomies (surgi-
cal, cryo, yttrium implants, etc.) are becoming a more
common cause of the disorder. Tumors are usually
of the suprasellar variety (craniopharyngiomas and
cysts) while anterior pituitary adenomas almost never
cause diabetes insipidus. Of the metastatic neo-
plasms, the ones from the breast are most common.
More rarely the disease is caused b' vascular abnor-
malities, infections, granulomatous disease or his-
tiocytosis. Finally, there is a rare familial form of
diabetes insipidus which is probably due to a defi-
ciency of vasopressin-synthesizing cells in the hypo-
thalamic nuclei [11]. This is an interesting contrast to
the pathology in the rat with hereditary pituitary
diabetes insipidus in whom the cells are hypertro-
phied and who probably has a defect in hormone
synthesis [12].
1. Clinical features. Polyuria and polydipsia, which
depending on the severity of the disease can range
from 3 to 15 liters/24 hr, are the hallmark of this
disorder. The disorder is equally frequent in both
sexes and the onset of symptoms is usually abrupt.
The age of onset is variable, but is most frequent in
the 10- to 20-yr age group and very uncommon in
infancy. Patients have an interesting predilection in
their thirst habits for cold water [13]. Symptoms have
little diurnal variation and thus nocturia is frequent.
However, in the untreated patient, marked bladder
enlargement and hydroureter may supervene at the
expense of renal function and increase bladder capac-
ity so that nocturia may be minimal. In the untreated
state, if the thirst mechanism is intact and water made
available, these patients can remain asymptomatic
except for the inconvenience of polyuria and poly-
dipsia. If, however, a patient with severe diabetes
insipidus has no water access or suffers from con-
comitant hypodipsia, life-threatening water depletion
and hypernatremia can ensue [14].
2. Diagnosis. The diagnosis of pituitary diabetes
insipidus should be entertained in any adult patient
with severe polyuria or polydipsia not undergoing a
solute (glucose, urea, mannitol or saline) diuresis.
The disease is best diagnosed by demonstrating a
defect of vasopressin secretory ability in response to
maneuvers that stimulate the endogenous release of
the hormone. A number of both osmotic and non-
osmotic stimuli have been employed as diagnostic
tests. The infusion of hypertonic saline (300 ml of 5%
NaCI) to increase plasma osmolality has been widely
used [15, 16]. Within 30 to 60 mm such an infusion
causes an antidiuresis in normal subjects but not in
patients with diabetes insipidus. The use and inter-
pretation of the test, however, calls for some pre-
cautions. It is important to document that the in-
fusion has indeed achieved an increase in plasma
osmolality that exceeds the osmotic threshold (ap-
proximately 292 mOsm/kg H20). This is particularly
in patients with compulsive water intake who may
have plasma osmolalities near 270 mOsm/kg H20
prior to the hypertonic infusion. Another precaution
relates to the large saline diuresis that can follow the
hypertonic infusion. In this setting urine output may
not significantly decrease even though a fall in free
water clearance has occurred. It is, therefore, impor-
tant to measure urine and plasma osmolality as well
as urine flow so that free water clearance can be
calculated. Finally, in patients with cardiac disease
the potential cardiovasular complications of acute
volume expansion with hypertonic saline may not
allow the use of this test.
Nicotine, a known stimulant of vasopressin re-
lease, also has been employed to assess posterior
pituitary function [17]. However, the i.v. administra-
tion of this agent causes nausea and occasional syn-
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cope, as well as alterations in systemic and renal he-
modynamics. These latter changes may alter urine
flow independent of vasopressin secretion. In view of
the shortcomings of the hypertonic saline and nico-
tine tests, fluid restriction followed by the administra-
tion of exogenous ADH is now the preferred test
for pituitary diabetes insipidus [18]. The test is per-
formed by restricting fluid intake until the patient
loses approximately 3 to 5% of body weight or until
three consecutive hourly urines show no further in-
crease in urinary osmolality. This usually occurs after
12 to 16 hr of fluid deprivation. At this time a sub-
cutaneous injection of 5 U of aqueous vasopressin is
administered to examine whether any further increase
in urinary osmolality can be achieved. The test has to
be carried out under careful supervision to ensure
that the patient does not continue to drink (e.g.,
compulsive water drinker) or does not become rap-
idly dehydrated and hypotensive (complete pituitary
diabetes insipidus.).
The fluid deprivation test has the advantage of
differentiating patients with partial defects in ADH
release from patients whose polyuria and polydipsia
is due primarily to an increase in water intake (com-
pulsive water drinking). As noted in Table 1, which is
adapted from the results of Miller et al [18], patients
with either total or partial diabetes insipidus signifi-
cantly increase their urinary osmolality when given
exogenous vasopressin after a period of fluid depriva-
tion. In contrast, patients with primary polydipsia
(compulsive water drinking) have a lower urinary
osmolality after fluid restriction than normal subjects
and this urinary osmolality does not increase further
with exogenous vasopressin administration. This at-
tests to the intactness of the vasopressin secretory ca-
pacity as well as the impaired renal response to vaso-
pressin which occurs in patients who have a high
water intake [19]. In view of their large intake of water,
patients with compulsive water drinking can present
with polyuria and polydipsia in the range observed in
patients with complete diabetes insipidus. These two
groups of patients, however, are different in several
aspects. The polydipsia is generally of abrupt onset in
the patient with pituitary diabetes insipidus while a
more vague history of onset is present in the com-
pulsive water drinker. A psychiatric history also is
frequently present in the compulsive drinker. Com-
pulsive water drinkers also generally have a lower
plasma osmolality (usually below 280 mOsm/kg
H20) as compared to the patient with diabetes insip-
idus [19]. Although patients with complete diabetes
insipidus do not attain a urine as concentrated as
plasma with fluid deprivation, the compulsive water
drinkers almost invariably excrete a modestly hyper-
tonic urine following water deprivation. As noted
above, the administration of exogenous vasopressin
after fluid deprivation will differentiate the patients
with primary polydipsia from those with partial de-
fects of ADH secretion.
3. Treatment. a. Hormonal replacement. Since
ADH is commercially available, it has become the
mainstay in the therapy of patients with pituitary
diabetes insipidus. The most commonly used prepa-
ration is pitressin tannate in oil (5 U/mI). There is
considerable variability in requirements, but usually
0.5 ml every 48 hr is sufficient for good control of
symptoms. It is important to remember that the
active hormone (arginine vasopressin) settles as a
brown speck at the bottom of the vial. Warming and
vigorous shaking is important to provide uniform
dispersion and thus prevent injection of oil without
the active hormone.
The oil preparation is best suited for patients with
well defined chronic disease. On the other hand, in
acute settings such as skull fractures or post-
hypophysectomy, the short-acting aqueous pitressin
(20 U/ml) (now in very limited world-wide supply)
should be given in a dose of 0.1 to 0.3 ml every four to
six hours. The shorter duration of action of this prep-
aration allows for closer monitoring of what may be
transient diabetes insipidus and thus makes the oc-
currence of water intoxication much less likely. In
addition to these parenterally administered prepara-
tions, vasopressin is also available for administration
via the nasal mucosa. The use of pitressin snuff has
been limited because it frequently causes irritation of
nasal passages. A nasal spray of synthetic lysine vaso-
pressin (Diapid, 50 U/ml), although less potent, is
stable, less toxic and better tolerated. These nasal
preparations are short-acting and useful only as ad-
juncts to pitressin tannate in oil. More recently, a
vasopressin analogue (I -deamino, 8 D-arginine vaso-
pressin, DDAVP) has been used. This analogue has a
Table I. Differentiation of polyuric disorders by dehydration
and exogenous ADH
Uosm by
dehydration
Uosm after
vasopressin
% change
in Uosm
Normal
(N = 9) 1067 68.7 978.0 79.4 —8.9 3.0
Diabetes
insipidus(N = 18) 168 13,0 445.0 52.0 183.0 41.4
Incomplete
diabetes
insipidus(N = 12) 437 33.6 548.0 28.2 28.5 4.7
Primary
polydipsia(N = 7) 738 52.9 779.8 73.1 5.0 2,2
Adapted from the findings in [18].
120 Ben el a!
longer half-life and greater antidiuretic potency than
the parent hormone [20, 21]. A dose of 10 to 20 iU
given nasally seems to achieve adequate control of
urine flow for as long as 20 hr. All patients receiving
ADH preparations should be warned against exces-
sive water intake to avoid water intoxication.
b. Pharmacologic agents. As was discussed by
Miller and Moses in this symposium [22], a number
of pharmacologic agents acting either centrally or
peripherally are endowed with antidiuretic proper-
ties. Of these the most commonly employed agent
is chlorpropamide (Diabenese). Since at least some
vasopressin needs to be present for this drug to be
effective, its usefulness is limited to those patients
with partial diabetes insipidus who account for 60 to
80% of patients. Once the diagnosis of diabetes insip-
idus is established, a trial of chlorpropamide (250 mg
q.d. or b.i.d.) may be instituted. The response to
chlorpropamide may not occur until three to seven
days. In some patients a profound decrease in poiy-
uria and polydipsia occurs, thus obviating the need
for treatment with vasopressin. Patients need to be
warned about the possibility of hypoglycemia with
chlorpropamide, especially during fasting. Hypona-
tremia also has been reported with chiorpropamide
[23] but the incidence is controversial [24, 25]. The
anticonvulsant carbamezapine (Tegretol) [26, 27] and
the hypolipemic agent clofibrate (Atromid-S) [28]
may induce an antidiuresis in some patients with
central diabetes insipidus, and a combination of ei-
ther of these drugs with chiorpropamide may provide
a synergistic effect [29]. Whether other agents that
have been found to affect water movement such as
acetaminophen [30] or indomethacin [31] have signif-
icant antidiuretic properties in man to warrant their
use in these patients has not yet been determined.
Vasopressin-resistant (nephrogenic) diabetes insip-
idus. 1. Congenital nephrogenic diabetes insipidus. The
term "congenital nephrogenic diabetes insipidus" is
applied to a rare familial disorder in which no signifi-
cant urinary concentration occurs in spite of the pro-
duction of normal amounts of vasopressin [32, 33].
All of the affected individuals may be descendants of
an Ulster Scotsman who arrived in the Western Hem-
isphere on the U.S.S. Hopewell in 1761 [34]. The
genetics of the disease have not been fully elucidated.
Females can have a mild subclinical disorder that
becomes evident only with fluid deprivation or the
administration of exogenous ADH. The complete
form of the disease occasionally occurs in the female
but is the only form encountered in males [35]. The
mechanism whereby the renal tubules are insensitive
to the hormone has not been fully defined. Some
studies have demonstrated a failure of ADH to in-
crease urinary cyclic adenosine monophosphate
(AMP) excretion in patients with nephrogenic diabe-
tes insipidus [36]. The observation that mice with
inherited vasopressin-resistant concentrating defects
cannot maximally stimulate adenyl cyclase with
ADH [37] also has raised the possibility that failure
of vasopressin to generate its intracellular mediator
(cyclic AMP) is responsible for the disorder.
Although the disease is inborn, the diagnosis of
congenital nephrogenic diabetes insipidus is made
only when the infant presents with hypotonic urine
associated with dehydration, vomiting and fever.
While the female with partial disease may elaborate a
hypertonic urine, the afflicted males' urine remains
hypotonic even in the face of severe dehydration and
the administration of exogenous vasopressin. Occa-
sionally, physical and mental retardation occur in
these infants, not as an integral component of the
disease, but probably as a consequence of repeated
episodes of hypertonic dehydration.
Since neither vasopressin nor agents that enhance
its action can effectively concentrate the urine of
these patients, the management of their polyuria is
more difficult. Adequate fluid intake and careful
monitoring of fluid balance is especially important,
particularly in children in order to prevent some of
the noted consequences of dehydration. When oral
intake is not possible, 2.5% or 3% dextrose should be
given to minimize urinary solute excretion [38]. Di-
uretics, which by virtue of volume contraction en-
hance proximal fluid reabsorption and decrease distal
fluid delivery, have met with some success in the
management of these patients [39]. Volume con-
traction must, however, be maintained by low so-
dium intake for this therapy to remain effective.
Recently, indomethacin also has been found to be
effective in treating patients with congenital nephro-
genic diabetes insipidus and to further potentiate the
effect of diuretics in this disorder [40]. Urinary cyclic
AMP excretion did not rise during the treatment, and
the mechanism of the effect remains unknown. Al-
though no form of treatment has resulted in the elab-
oration of a hypertonic urine, diuretic therapy can
decrease daily urine flow from severe (10 to 12 liters/
day) to more tolerable (usually 3 to 5 liters/day)
levels. This is of importance not only in relieving the
inconvenience associated with the large intakes and
outputs of fluids but also to minimize the functional
dilatation of the urinary tract that accompanies such
states. In the absence of effective treatment, bilateral
hydroureters and hydronephrosis may develop and
cause renal impairment.
2. Acquired nephrogenic diabetes insipidus. In a
number of physiologic, pathologic and pharma-
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cologic conditions, the kidney's capacity to elaborate
a maximally concentrated urine is impaired in spite of
the presence of supraphysiologic levels of circulating
vasopressin. While this acquired form of nephrogenic
diabetes insipidus is much more common than the
congenital form, it is rarely as severe. The ability to
concentrate the urine to the level of plasma is usually
preserved and this significantly decreases the oblig-
atory urine losses; thus, polyuria and polydipsia are
usually moderate (3 to 5 liters/24 hr). Some of the
causes for acquired nephrogenic diabetes insipidus
will now be discussed.
a. Chronic renal disease. A decrease in glomerular
filtration rate affects the ability of the kidney to max-
imally concentrate the urine, and the defect is mostly
pronounced when the glomerular filtration rate falls
below 60 mI/mm [41]. Diseases which affect primar-
ily the papillary and medullary region of the kidney
such as medullary cystic disease [42], polycystic dis-
ease [42], obstructive uropathy [43], amyloidosis [44],
pyelonephritis [45], radiation nephritis [46], Sjögren's
syndrome [47], sickle cell disease [48] and light chain
nephropathy [49] tend to have the earliest and most
severe defects. It must be emphasized, however, that
any form of advanced renal disease, including gb-
merular and vascular disease, may culminate in a
state of vasopressin-resistant hyprosthenuria [50]. In
spite of vasopressin-resistant hypotonic urine, the
polyuria and polydipsia in these patients with chronic
renal disease is generally not severe because of the
decreased glomerular filtration rate.
The pathogenesis of the concentrating defect in
chronic rercal failure is probably multifactorial. It can
be readily appreciated that pathologic abnormalities
in the renal medulla may disrupt the important ana-
tomical relationship among the loop of Henle, the
vasa recta and the collecting duct and thereby impair
maximal concentrating ability. The existence of a
uremic toxin that antagonizes the action of vasopres-
sin also is possible but remains speculative. Lastly, as
the nephron population decreases in chronic renal
disease, each remaining nephron is essentially in a
state of osmotic diuresis. Even in the normal kidney,
such an osmotic diuresis per nephron may lead to the
excretion of a urine approaching isotonicity even in
the presence of vasopressin [51].
b. Dietary abnormalities which may cause nephro-
genic diabetes insipidus. Extreme dietary alterations in
the intake of protein, sodium chloride and water may
affect maximal concentrating capacity. The impair-
ment that is associated with a decrease in protein in-
take [52] is most likely related to the decreased avail-
ability of urea which normally accounts for about
50% of the medullary interstitial tonicity during the
antidiuretic state. Likewise, a marked restriction of
sodium chloride intake may cause a similar con-
centrating defect [53]. Since active chloride and pas-
sive sodium reabsorption in the thick ascending loop
constitutes the first step in the normal operation of the
countercurrent multiplier, sodium chloride restriction
may enhance proximal reabsorption of these ions and
thereby limit their delivery to the ioop of Henle.
Finally, while it has been recognized that prolonged
dehydration enhances the concentrating mechanism,
a state of chronic overhydration may impair maximal
urinary concentration. As previously noted, this is
particularly striking in patients with primary poly-
dipsia who have a marked concentrating defect even
when water-restricted or given exogenous vasopres-
sin [19]. The defect is probably due to the fact that
chronic ingestion of excessive volumes of water
causes a lowering of medullary interstitial tonicity.
An interference with the action of vasopressin at the
level of the renal tubule, however, has not been as-
sessed and remains a possibility.
c. Electrolyte disturbances causing acquired nephro-
genic diabetes insipidus. It is widely recognized that
hypercalcemia of various etiologies may cause a vaso-
pressin-resistant urinary concentrating defect [54].
The mechanism of this defect is somewhat con-
troversial. The medullary calcium deposits, as well
as the decrement in glomerular filtration, which fre-
quently accompany hypercalcemia may interfere with
the generation of a hypertonic medullary interstitium.
Other studies in which medullary solutes were found
to be normal [55], however, suggest a disturbance
involving an incomplete osmotic equilibration. This
may occur when the collecting duct fails to achieve
maximal water permeability. Such a direct cellular
effect of hypercalcemia has gained support from the
in Vitro observations that increased calcium concen-
trations inhibit the hydroosmotic effect of vasopres-
sin in the toad bladder [56] and inhibit adenyl cyclase
activation [58] and cyclic AMP formation in the
renal medulla [57].
A renal concentrating defect also occurs in associa-
tion with hypokalemia in man [59] and experimental
animals [60]. In this setting, a diminished medullary
tonicity also has been implicated as the cause of the
derangement in the countercurrent system [61]. How-
ever, the ratio of urinary to papillary solutes has been
found to be diminished in the potassium-depleted rat
[62], thus suggesting failure of complete osmotic
equilibrium between the interstitium and tubule fluid.
Also, potassium depletion in the toad bladder has
been found to impair the response to vasopressin
[63], thus suggesting that the defect may reside in the
cellular action of vasopressin. A recent study per-
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formed in medullary slices of hypokalemic rats sug-
gests an impairment of ADH-stimulated adenyl cy-
clase and cyclic AMP formation [64]. However, in
agreement with Pawlson et al [65], we have recently
observed that the concentration of medullary cyclic
AMP is actually higher in potassium-depleted rats
[66]. Thus, further studies are needed to investigate
any abnormality at the level of the renal tubule.
Independent of the mechanism it must be empha-
sized that the concentrating defect in both hypercal-
cemia and hypokalemia is modest and, thus, marked
polyuria and polydipsia should not ensue. The fre-
quently observed fluid intake of more than 3 liters/
day has led some authors to postulate a primary
effect of these electrolyte disturbances to stimulate
thirst [67]. The correction of the electrolyte abnor-
mality normalizes renal concentrating capacity in
most, albeit not all, patients [54].
d. Sickle cell disease. The propensity of red blood
cells in patients with sickle cell disease to become
sickle-shaped in the low oxygen-tension hypertonic
medulla [68] disturbs the circulation of vasa recta
[69] and causes edema of the renal papilla [48]. These
pathologic changes are probably responsible for the
observed renal concentrating defect in both hetero-
zygote and homozygote patients with this disorder of
hemoglobin metabolism. Evidence that the primary
defect resides in the red blood cells is corroborated by
the ability to correct the defect by whole blood trans-
fusions, particularly in children [70]. In the adult,
renal medullary infarcts are present and the renal
concentrating defect is generally irreversible.
e. Pharmacologic agents causing nephrogenic dia-
betes insipidus. An increasing number of pharma-
cologic agents have been noted to interfere with max-
imal urinary concentration by a direct renal action.
Such drugs include lithium carbonate [71], deme-
clocycline [72], amphotericin B [73], methoxyflurane
[74] and others that are fully discussed in the paper
by Singer and Forrest in this symposium [75]. The
possible role of drugs, therefore, must be considered
in the evaluation of any patient with polyuria and
polydipsia.
Approach to the hypernat rem/c patient. Sodium and
its accompanying anion are the primary determi-
nants of the osmolality of extracellular fluid (ECF).
Because of the permeability of all membranes to
osmotic water movement, an increase in ECF os-
molality also indicates a hyperosmolar state of in-
tracellular fluids [76]. Unlike urea or ethanol, so-
dium, is actively pumped out of cells; thus, a rise in
ECF sodium concentration results in intracellular de-
hydration. Such hypernatremic states may be due to
the net loss of hypotonic body fluids either by renal
or extrarenal routes. However, the thirst mechanism
is so sensitive to hyperosmolarity (1 to 2%) that se-
vere hypernatremia is rarely observed unless the
patient has a neurologic disease associated with
hypodipsia or does not have free access to water.
Hypernatremia is, thus, most commonly seen in
patients who are comatose or who have a primary
disturbance of thirst. The cellular dehyration which is
associated with hyperosmolar states may lead to al-
terations in mentation and level of consciousness.
The hypernatremic patient also can present with con-
vulsions and the cerebrospinal fluid may be xan-
thochromic due to capillary rupture [12].
As depicted in Fig. 1, hypernatremia can develop
in the setting of low, normal or rarely high body
sodium. Thus, the determination of ECF volume
status is critical to the diagnosis of the cause of the
hypernatremia, as well as the management of such
patients.
1. Hypernatremia and low total body sodium. Hy-
pernatremia in the setting of low total body so-
dium occurs in patients who sustain losses of both
sodium and water, but with a relatively greater loss
of water. Such patients display the signs of volume
contraction such as flat neck veins, orthostatic hy-
potension and tachycardia, poor skin turgor and dry
mucous membranes. The hematocrit and serum pro-
tein concentrations generally are increased due to
the hemoconcentration. The hypotonic fluid losses
can occur through the skin, as with profuse sweating,
or from the gastrointestinal tract, particularly as-
sociated with diarrhea in children. In these condi-
tions, urinary osmolality is appropriately high and
urinary sodium is below 10 mEq/liter. In contrast,
if the losses are of renal origin, urinary sodium
will be higher and urinary osmolality will approach
isotonicity or even become hypotonic. Hyperna-
tremia associated with volume depletion due to renal
losses of hypotonic fluid occurs during an osmotic
diuresis. The osmotic diuresis causes renal sodium
losses, and the urinary sodium concentration is well
above 10 mEq/liter. The osmotic diuresis may be due
to I) glucosuria as in diabetes mellitus, 2) urea as in
association with tube feedings of high protein content
or relief of bilateral ureteral obstruction or 3) manni-
tol following its administration. It must be noted that
in the presence of either glucose or mannitol in the
circulation, these substances will exert an osmotic
force to move water from the cellular to extracellular
compartment. Thus, despite hypotonic renal losses,
the plasma sodium concentration may be normal or
even decreased.
Although the underlying cause of the hypertonic
state needs to be treated, the immediate management
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Fig. 1. Clinical approach to the patient with hypernatremia.
of the electrolyte disorder depends on the clinical
status of the patient. Thus, if severe circulatory dis-
turbances are noted, treatment with isotonic sodium
chloride should be instituted until systemic hemody-
namic alterations are corrected; then further correc-
tion of the hypernatremia can be achieved with
5% dextrose or 0.45% NaC1. Correction of hyperna-
tremia, particularly in children, should be undertaken
slowly to prevent neurologic disturbances, such as
grand mal seizures.
2. Hypernatremia and normal total body sodium.
A deficit of water without solute generally does
not lead to overt signs of hypovolemia unless the
losses are massive. Because of the total body distribu-
tion of water, only 8% of a negative water balance is
at the expense of intravascular volume. Water losses
occur through the skin and the upper respiratory
tract. Such "insensible losses" of fluid increase in
high temperature environments, and in febrile and
hypermetabolic states. Such water losses can lead to
hypernatremia if the subject is unable to replace these
losses by drinking. In this setting the urine is concen-
trated since the resultant hyperosmolality stimulates
ADH release.
In contrast, if the water losses causing hyperna-
tremia are of renal origin, the urine is hypotonic.
Such is the situation with pituitary or nephrogenic
diabetes insipidus.
Patients in whom "essential hypernatremia" has
been diagnosed are characterized by the absence of
ECF volume depletion, a capacity to release endog-
enous vasopressin and a normal renal response to
vasopressin [77]. These patients have a blunted or
absent thirst perception despite rather severe hyper-
osmolality. A review of reported patients with this
diagnosis reveals that most [78—80], although not all
[81], have intracerebral lesions which are most com-
monly situated in the hypothalamus. Vasopressin se-
cretion as evidenced by the ability to concentrate the
urine has been documented in most of these patients.
Some have postulated that the hypernatremia in these
patients is due to a resetting of the osmoreceptors.
Such a concept would require that the sensitive regu-
lation of serum tonicity takes place at a higher "re-
set" level. At this new "reset" level, urinary dilatation
would occur with minimal hypoosmolality (1 to 2%)
and urinary concentration would occur with minimal
hyperosmolality (I to 2%). Most of the reported
patients, however, do not fulfill these criteria. It is
clear that some of the reported patients have had at
least a partial defect of vasopressin secretion [80, 821.
In this setting, large increments in plasma osmolality
are necessary to stimulate vasopressin release. In
some patients the release of vasopressin has been
found to be stimulated to a greater degree by volume
depletion or hypotension than by increases in plasma
osmolality. When the patient becomes severely vol-
ume-depleted, enough vasopressin may be released to
maximally concentrate the urine [79, 83].
The treatment of hypernatremia which has resulted
from water deficits involves primarily the replace-
ment of the water deficit. This deficit can be estimated
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on the basis of the serum sodium concentration. For
example, the total body water of a patient weighing
75 kg can be estimated to be 60% of body wt (75 kg X
0.6 = 45 liters). At a serum sodium concentration
of 154 mEq/liter, the water needed to lower so-
dium concentration to 140 mEq/Iiter would be cal-
culated as follows: 154 mEq/liter/140 mEq/liter X
45 liters = 49.5 liters. Therefore, a net deficit of 4.5
liters (49.5 — 45.0 liters) needs to be replaced. This
can be achieved by either oral intake, 5% dextrose
infusions or tap water enemas. Chlorpropamide (250
mg/day) has been used in some patients with essen-
tial hypernatremia [78, 84]. While the drug probably
has no effect on the thirst center [80], it improves
urinary concentration and, thus, water conservation
in those patients in whom partial diabetes insipidus
and hypernatremia coexist [78, 84].
3. Hypernatremia and high total body sodium. The
development of hypernatremia in the setting of a
high total body sodium is not as common as the
previous categories. This is because the kidney is
generally capable of excreting any excess sodium
which is ingested. Mild elevations of serum sodium
concentration (145 to 150 mEq/liter) may be ob-
served in primary aldosteronism and in Cushing's
disease [12]. This small change in plasma sodium
concentration may be due to a slight increase in os-
motic threshold which is caused by the associated
volume expansion. Most other causes of hyperna-
tremia in this setting are iatrogenic (NaHCO3 admin-
istration during resuscitation) or accidental (hyper-
tonic NaCI entering the circulation in an abortion
attempt or inadvertent dialysis against a high sodium
bath). Such rapid and massive increases in sodium
draw water from the cells and may culminate in pul-
monary edema. In a hot, humid environment, the
ingestion of salt tablets without adequate water in-
take may lead to severe hypernatremia. The excessive
sodium can be removed by either diuretics or, if renal
function is impaired, by dialysis as water losses are
replaced either parenterally or orally.
Disorders of urinary dilution
The ability of normal man to drink as much as 25
liters of water per day without developing water re-
tention reflects the kidney's ability to excrete large
volumes of dilute urine. This diluting ability is depen-
dent on I) normal delivery of fluid to the diluting
segment of the nephron, i.e., normal rate of glomeru-
lar filtration and proximal tubular reabsorption; 2)
sodium chloride reabsorption in the water-imper-
meable ascending limb of Henle's loop; and 3) ab-
sence of circulating vasopressin or any other sub-
stance or anatomical damage that could render the
collecting duct epithelium permeable to water.
While an excessive water intake may occasionally
cause hyponatremia despite intact renal function and
normally suppressed plasma concentrations of ADH
(e.g., drinking from a faucet, shower or hose), in
general the development of hyponatremia occurs at
much lower intakes of water. Such hyponatremia
reflects an impairment in renal water excretion which
is due to continued secretion of ADH or some in-
trarenal abnormality in urinary dilution. Since the
presence of a hypoosmolar state should suppress the
secretion of vasopressin, the persistent release of
vasopressin in association with hyponatremia in-
dicates either a faulty osmoreceptor system or the
presence of more potent, nonosmotic stimuli for
ADH release.
Approach go the hyponatremic patient. The clinical
disorders and the signs and symptoms associated
with hyponatremia are listed in Tables 2 and 3, re-
spectively. The diagnostic and therapeutic approach,
which is outlined in Fig 2, is based on the recognition
of the hyponatremic patient's ECF volume which
may be diminished, expanded or normal. Also, an
analysis of the urinary sodium concentration in such
hyponatremic patients may be of diagnostic aid in
determining the etiology of the hyponatremia.
1. Hyponatremia without an associated decrease in
serum osmolablity or alteration in total body water.
A decrease in serum sodium concentration that is
not accompanied by a decrease in plasma osmolality
should arouse the suspicion that a substance that
does not freely diffuse across cell membranes is cir-
culating in high concentrations. Such a substance
would tend to draw water from the intracellular
space in order to maintain osmotic equilibrium and
will thereby decrease the concentration of sodium
in ECF. Glucose [85] and, occasionally, mannitol
[86] are most often responsible for such a process.
Since both substances have a mol wt of 180, their
contribution to plasma osmolality can be obtained
by dividing their concentration (mg/liter) by 18.
The low plasma sodium concentration in these cir-
cumstances is an accurate reflection of the sodium
Table 2. Clinical circumstances associated with hyponatremia5
Pseudohyponatremia
Congestive heart failure
Advanced hepatic cirrhosis
Nephrotic syndrome
Chronic renal failure
Decreased intravascular or extracellular
fluid volume
Emotional and physical stress
Endocrine disorders
Pharmacologic agents
Syndrome of inappropriate ADH
secretion
Adapted from SCHRIER RW, BERL T: Hyponatremia and related
disorders, in The Kidney, 1974, vol. 7, p. I
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Table 3. Signs and symptoms that may be associated
with hyponatremia
Symptoms Signs
Lethargy, apathy Abnormal sensorium
Disorientation Depressed deep tendon reflexes
Muscle cramps Cheyne-Stokes respiration
Anorexia, nausea Hypothermia
Agitation Pathological reflexes
Pseudobulbar palsy
Seizures
concentration of ECF but is not associated with an
alteration in total body water. Rather, it is the distri-
bution of water between cellular and extracellular
spaces that is disturbed. This abnormal distribution
and the low serum sodium concentration that accom-
panies it will correct as soon as the elevated concen-
trations of glucose or mannitol decrease.
A factitiously low serum sodium concentration is
reported by the laboratory when the plasma concen-
tration of lipids or proteins is very high and thereby
occupies a significant volume of the plasma [87, 881.
In this setting the sodium concentration is normal
when measured in plasma water, but it is decreased
when measured routinely in total plasma containing
the increased lipids or proteins. The plasma os-
molality is, however, normal. Finally, a laboratory
error or a sample improperly drawn above an in-
fusion of hypotonic solution should be considered
before measures to diagnose the cause of a patient's
hyponatremia are embarked upon.
2. Hyponatremia associated with in creased total
body sodium. Hyponatremia may occur in patients
with advanced congestive heart failure, hepatic cir-
rhosis and nephrotic syndrome [89, 97] who have
an increase in total body sodium but an even larger
increase in total body water. The pathogenesis of the
impaired renal diluting capacity of these disorders has
not been clearly elucidated. The decrease in "effective
blood volume" which is associated with a decrease in
cardiac output (cardiac failure), decreased peripheral
resistance (cirrhosis), increased splanchnic venous
pooling (cirrhosis) or hypoalbuminemia (cirrhosis,
and nephrotic syndrome) may activate mechanisms in-
volved in both sodium and water retention. The water
retention may be mediated by activation of barorecep-
tors leading to decreased afferent parasympathetic
tone and vasopressin release [98]. A role for persistent
secretion of ADH has been supported by the finding
of elevated concentrations of AD H-like material in
the serum and urine of some patients with hepatic cir-
rhosis, nephrotic syndrome and congestive heart failure
[99-101]. However, elevated plasma ADH concentra-
tions have not been found uniformly, although little
data are available using radioimmunoassay techniques
[99—101]. Ethyl alcohol, an inhibitor of ADH secre-
tion, has improved the impaired water excretion in
some, but not all, hyponatremic patients with heart
failure and hepatic cirrhosis [94—96]. Recent labora-
tory studies utilizing models of heart failure and cir-
rhosis also suggest that ADH may play a major role
in the impaired renal water excretion of these dis-
orders [98, 102]. Other possible AD H-related mecha-
nisms resulting in impaired renal water excretion in
these states include either enhanced renal tubular
sensitivity to ADH or prolonged ADH half-life re-
sulting from delayed metabolic clearance rates of
ADH. These possibilities appear unlikely since com-
parable antidiuretic responses (in terms of both dura-
tion and magnitude) to exogenously administered
Hyponatremia
Deficit of total budy water IExcess total body water Excess total body sodium
and larger deficit
of total body sodium
and larger excess of total
body water
I[CF column depletion Modest [CF volume excess IECF volume excess
no edema) edema)
-
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Fig. 2. Clinical approach to the patient with hyponatremia.
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ADH have been observed in patients with heart fail-
ure and hepatic cirrhosis when compared with nor-
mal controls [89, 91, 92]. However, a recent prelimi-
nary report utilizing more sensitive techniques sug-
gests that a diminished metabolic clearance rate of
ADH results in a prolonged ADH half-life and ele-
vated ADH concentrations in patients with hepatic
cirrhosis [101]. In this latter study there was no evi-
dence for an increased release of ADH in cirrhotic
patients.
Since patients with heart failure, hepatic cirrhosis
and nephrotic syndrome also frequently have dimin-
ished effective circulating blood volumes, these dis-
orders may be associated with decreased glomerular
filtration rate and enhanced proximal reabsorption
of tubular fluid. Such a diminution in glomerular
filtration rate and increased proximal nephron reab-
sorption may limit renal water excretion by decreas-
ing delivery of tubular fluid to the diluting segment of
the nephron [103, 104]. Consistent with this hypoth-
esis as a cause of impaired renal diluting capacity in
these edematous disorders has been the finding that
infusion of mannitol or furosemide may convert hy-
pertonic to hypotonic urine in patients with heart
failure, cirrhosis and nephrosis [9 1—93]. However,
both of these drugs may have effects in addition to
enhancing delivery of tubular fluid to the distal neph-
ron. For example, mannitol can result in volume
expansion and thus suppress ADH secretion. Fur-
thermore, since exogenous ADH does not return fu-
rosemide-induced hypotonic urine to a hypertonic
state [93], these studies do not exclude a role for
ADH-mediated alterations in renal water excretion in
these disorders. In summary, the contributions of
presistent ADH secretion and of intrarenal mecha-
nisms in the impaired renal water excretion of heart
failure, hepatic cirrhosis and nephrosis remain to be
fully elucidated. Since sodium reabsorption is very
avid in these edematous disorders, unless the patient
is receiving natriuretic doses of diuretics, the urinary
sodium concentration will usually be below 10
m Eq/liter.
Another group of patients that may present with
evidence of increased total body sodium and hypo-
natremia is patients with advanced renal failure who
have ingested excessive water. In contrast to the
above group of patients, the patient with renal failure
and hyponatremia frequently has a higher urinary so-
dium concentration. Patients with advanced renal dis-
ease may dilute their urine; therefore their impaired
water excretion is primarily due to severe reduction in
glomerular filtration rate rather than to a defect in in-
trarenal diluting mechanisms [105]. Thus, with a gb-
merular filtration rate of 5 mI/mm (7 liters/day) and
an estimated 20% of this filtrate reaching the dilut-
ing segment of the nephron, a maximum of only 1.4
liters/day of free water may be generated. Intake in
excess of this amount will result in hyponatremia.
The frequent occurrence of hyponatremia with severe
reductions in glomerular filtration rate is suggested
by the finding that 50% of patients with acute renal
failure develop serum sodium concentrations less
than 130 mEq/liter during the oliguric phase of their
illness [106].
The therapy of hyponatremia in patients with both
increased total body sodium and water should be
lirected at maximal improvement of the underlying
disorder. Since these patients already have an in-
creased total body sodium, efforts to increase serum
sodium through saline administration will result in
only further expansion of ECF volume and may
worsen the clinical status of the patient. Attempting
to decrease total body water by severe fluid restric-
tion is the most appropriate therapy. The excess in
body sodium needs to be concomitantly treated by
sodium restriction and the judicious use of diuretics.
3. Hyponatremia associated with decreased total
body sodium. Of the nonosmolar factors that control
the secretion of vasopressin, the volume status of the
individual may be the most important one. Since at-
tempts to maintain a normal circulating blood vol-
ume take priority over maintenance of tonicity in
hypovolemic states, vasopressin secretion and water
retention occur even at the expense of hypoosmolar-
ity. Patients who develop hyponatremia in this set-
ting have a deficit of both sodium and water, but a
greater deficit of the former.
As noted in Fig. 2, the fluid losses may occur by
either extrarenal or renal routes. Extrarenal losses
most commonly occur via the gastrointestinal tract
by vomiting or diarrhea but may be due to "third
space" fluid accumulation (burns, traumatized mus-
cle, pancreatitis, peritonitis). The normal kidney
responds to these hypovolemic states by conserving
sodium and water and, thus, a hypertonic urine with
a sodium concentration below 10 mEq/liter may be
expected. If renal function is abnormal, however,
sodium and water conservation may be defective and
the noted urinary indexes are not applicable.
If the source of the patient's fluid losses is renal, the
urinary sodium concentration is above 20 mEq/liter.
Such renal losses may be due to intrinsic parenchy-
mal renal disease, the use of diuretics or miner-
alocorticoid deficiency. While impaired renal sodium
handling usually accompanies advanced chronic
renal insufficiency, some patients with medullary cys-
tic disease, polycystic disease or other tubulo-inter-
stitial disorders may exhibit significant urinary so-
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dium losses with only moderate impairment of
function. These patients, therefore, will sustain a so-
dium deficit if their sodium intake does not at least
match the obligatory urinary losses [108]. It must be
noted also that some patients with type 11 (proximal)
renal tubular acidosis have significant bicarbonaturia
which obligates urinary sodium losses. These patients
will therefore not lower their urinary sodium max-
imally even in the face of volume contraction.
The use of diuretics also can lead to sodium-rich
renal fluid losses culminating in hypovolemia and
vasopressin secretion. Diuretics, however, can inter-
fere with urinary dilution by other mechanisms as
well. Because of their effect on circulating volume,
they may decrease glomerular filtration rate and in-
crease proximal fluid reabsorption, thus diminishing
tubular fluid delivery to the diluting segment. Fur-
thermore, some diuretics (furosemide, ethacrynic
acid and thiazides) act by inhibitng solute reabsorp-
tion in the diluting segment of the nephron and
thereby limit maximal free water generation. Finally,
potassium depletion per se, by mechanisms that re-
main to be elucidated, may lead to hyponatremia.
This is supported by the observation that in a few
patients potassium repletion alone returned the se-
rum sodium concentration to normal [107].
The hyponatremic, hypovolemic patient whose
urinary sodium concentration is above 20 mEq/liter
should raise the possibility of adrenal insufficiency,
particularly if the blood urea nitrogen and potassium
concentrations are elevated. The mechanisms
whereby this disorder causes an abnormality in renal
water excretion have been the subject of much con-
troversy [108—Ill] and are fully discussed in the
manuscript by McDonald et al [112] in this sympo-
sium. It appears, however, that the diluting defect as-
sociated with mineralocorticoid deficiency is related
to the accompanying negative sodium balance [Ill]
and probably mediated by an increase in vasopressin
secretion [113, 114], while the defect associated with
glucocorticoid deficiency is independent of volume
depletion but also is due partially to elevated concen-
trations of vasopressin [I 15J.
In contrast to the edematous patients, the treat-
ment of hyponatremia in a volume-depleted patient
should be directed to expansion of ECF volume with
normal sodium chloride. Such an approach will cor-
rect systemic and renal hemodynamics and thereby
allow the normal function of the osmoreceptor-ADH
system to normalize plasma osmolality. Attention
also needs to be directed to the patient's underlying
disease. Diuretics should be discontinued and potas-
sium supplementation be considered if the patient is
hypokalemic. Of course, hormonal replacement must
be instituted in patients suspected of having adrenal
insufficiency.
4. Hyponatremia with clinically undetectable altera-
lions in total body sodium. The long-term administra-
tion of exogenous vasopressin to normal subjects
allowed ad lib fluid intake leads to weight gain, a
concentrated urine and hyponatremia due primarily
to retention of water [116]. Since water is distributed
equally in both intracellular and extracellular space,
about 8% of retained water is contained in the vas-
cular space; thus, overt signs of hypervolemia, such
as edema, do not generally appear in this setting. It
is not surprising, therefore, that subjects who persist-
ently secrete vasopressin and do not curtail water in-
take will become hyponatremic, but not edematous.
A great deal of debate has centered around the
question of whether such vasopressin secretion is ap-
propriate or inappropriate [117]. Since the "phys-
iological" control of the vasopressin's secretion is not
exclusively under the control of ECF osmolarity, it
perhaps is not accurate to term as inappropriate the
persistence of vasopressin secretion which occurs in
response to a nonosmolar stimulus. Therefore, the
term "inappropriate" perhaps should be reserved for
those entities in which ADH secretion persists in spite
of the absence of known osmolar and nonosmolar
stimuli.
Rydin and Verney recognized in 1938 that emo-
tional stress could inhibit a water diuresis by a vaso-
pressin-mediated mechanism [118]. Since then,
patients have been reported in whom either pain
[119] or emotional stress [120] has caused abnormal
water excretion leading to hyponatremia. The hypo-
natremia that occurs in some patients with acute
intermittent prophyria [121] may be due to such
stress, but a decrease in blood volume as a stimulus to
the hormone's release also has been suggested [122].
While most patients receiving diuretics have a con-
tracted ECF volume, some develop hyponatremia
with no overt findings of volume depletion, perhaps
because it is obscured by the retention of water [107].
The abnormality in the secretion of a water load has
been used as a diagnostic test for primary or second-
ary adrenal insufficiency. As noted above, this abnor-
mality in urinary dilution that accompanies anterior
pituitary insufficiency [1101 and glucocorticoid defi-
ciency [115] can occur in euvolemic states and is
probably due, at least in part, to persistent secretion
of vasopressin. The mechanism that stimulates the
hormone's secretion in this state is not known, but
an alteration in cardiac function that could alter af-
ferent parasympathetic tone has been proposed [II 5J.
Alternatively, a direct effect of glucocorticoid hor-
mone on ADH synthesis or release could be involved.
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Patients with hypothyroidism who have neither
hypovolemia nor edema have a mild disturbance in
maximal urinary dilution [123, 124]. The possible
mechanisms whereby such a disturbance may ensue
have been fully discussed in this symposium by
McDonald et al [112]. It appears, however, that alter-
ations in renal hemodynamics in this hypometabolic
state can cause a defect independent of vasopressin
secretion [125]. However, in advanced myxedema,
the associated changes in cardiac output [126] may
activate baroreceptors and stimulate the secretion of
vasopressin. From a clinical point of view, the patient
with uncomplicated, mild hypothyroidism rarely
develops overt hyponatremia. However, the con-
comitant use of a pharmacologic agent with anti-
diuretic properties (e.g., chlorpropamide) or an
intercurrent illness that could cause vasopressin re-
lease makes these patients more prone to develop
hyponatremia.
The possible use of a number of pharmacologic
agents that either stimulate the release of vasopressin
or potentiate the peripheral action of the hormone
need to be considered in this group of hyponatremic
subjects. These drugs have been fully discussed by
Miller and Moses in a paper in this symposium [22]
and, therefore, will not be further discussed here.
Once all these clinical, physiologic and pharma-
cologic entities have been excluded in an apparently
envolemic patient, the syndrome of inappropriate
secretion of ADH (SIADH) should be considered.
Since first described by Schwartz et al in 1957 [127] in
two patients with bronchogenic carcinoma who were
clinically normovolemic with normal renal and ad-
renal function and had a less than maximally dilute
urine and appreciable urinary sodium concentrations
[124], the syndrome has been recognized in associa-
tion with a variety of pathologic processes. In gen-
eral, these processes have been neoplasms or involved
abnormalities of the central nervous system or lung
[128—130]. ADH-like material has been demonstrated
in some neoplasms. Moreover, production of ADH-
like material synthetized from amino acid precursors
has been demonstrated to occur [131]. Patients with
SIADH have a concentrated urine in spite of the
hyponatremia and the urinary sodium concentration
closely parallels the intake and is thus usually above
20 mEq/liter. In the presence of sodium restriction or
volume depletion, however, these patients can con-
serve sodium normally [132].
An entity called "sick cell syndrome" has been
proposed as another cause of hyponatremia with nor-
mal plasma osmolality [133]. This view suggests that
a variety of disorders may lead to selective alterations
in cell membranes so that sodium from ECF enters
"sick cells" and intracellular solutes from such "sick
cells" leave the cell. The exchange of sodium for
intracellular solute is equiosmolar so that no decline
in plasma osmolality would be expected. However,
in the vast majority of cases of hyponatremia, hy-
poosmolality indicating a relative water excess is
present. Moreover, the amount of solute needed to
enter cells to result in significant hyponatremia is
substantial and unlikely to be observed during life
[134]. Furthermore, there is no evidence that any
sodium that enters cells becomes osmotically inactive
and thereby leads to hyponatremia solely by its in-
tracellular location. Thus, the existence of the entity
of "sick cells" remains subject to serious doubt.
Recently, interest has been renewed in another en-
tity that may be associated with hyponatremia in the
normovolemic patient. A small number of chroni-
cally ill patients with mild hyponatremia and hy-
poosmolality have been demonstrated to I) normally
excrete a water load, 2) form hypertonic urine in
response to hypertonic saline or dehydration and 3)
not correct their hyponatremia in response to saline
loading [137]. These criteria have been proposed to
define hyponatremia due to a "reset osmostat". How-
ever, it should be noted that two of the three criteria
(2 and 3) also are seen in patients with SIADH,
Furthermore, since nonosmotic stimuli may alter the
osmotic threshold for ADH release, the "reset os-
mostat" may simply be a variant of SIADH, Thus,
further studies are needed to determine both the fre-
quency of this syndrome and whether it is a new
clinical entity.
The treatment of hyponatremia in patients with
SIADH depends on the clinical severity of the dis-
order and the presence or absence of the neurologic
signs listed in Table 3. In cases of mild asymptomatic
hyponatremia, water restriction that will result in net
negative water balance (usually <I liter/day) is the
preferred treatment. More aggressive therapy is in-
dicated in cases of severely symptomatic hypona-
tremia. Hypertonic saline therapy, which has been
recommended in the past, usually results in only min-
imal and transient increases in the serum sodium
concentration since, in the face of volume expansion
and a normal glomerular filtration rate, rapid urinary
sodium excretion occurs [1291. Moreover, this ther-
apy may be dangerous in elderly patients with bor-
derline cardiac status. More recently, by the use of a
potent loop diuretic (furosemide), replacement of in-
duced urinary electrolyte losses with 3% NaCI, rapid
net water balance and correction of severe hypona-
tremia has been achieved [136]. Finally, lithium and
demeclocycline have been demonstrated to inhibit the
hydroosmotic action of ADH as well as the increase
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in renal tissue cyclic AMP [71, 721. Preliminary re-
ports suggest that the administration of these agents
may be of value in the long-term therapy of chronic
SIADI-1 [137, 138].
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